drugset / Trial / NCT06615050
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Phase 3
Recruiting
572 enrolled
Incyte Corporation
Blood and Marrow Transplant Clinical Trials Network · collabNational Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Timeline
- Start
- 2025-04-02
- Primary completion
- 2031-01-17
- Completion
- 2031-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Comparator | Mycophenolate Mofetil | Small molecule | — | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |
| Background | Tacrolimus | Small molecule | — | Oral |